Job alerts from Tempest Therapeutics
Never miss new job openings
No, I'm not interested
Tempest is also developing an inhibitor of TREX-1, an exonuclease highly expressed in tumors that suppresses both STING and tumor immunity, to activate STING selectively in metastatic lesions via a systemically-delivered small molecule. Tempest is headquartered in South San Francisco and supported by notable healthcare investors. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Similar companies
See what companies are similar to Tempest Therapeutics
Pharmaceutical Manufacturers
Small size
Scientific Research & Development Firms
Small size
You comment as
